bluebird bio
BLUE
BLUE was delisted on the 30th of May, 2025.
83 hedge funds and large institutions have $411M invested in bluebird bio in 2014 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 39 increasing their positions, 17 reducing their positions, and 9 closing their positions.
129% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 17
44% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 9
9% more capital invested
Capital invested by funds: $378M → $411M (+$33M)
2% more funds holding
Funds holding: 81 → 83 (+2)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
78% less call options, than puts
Call options by funds: $20K | Put options by funds: $91K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$11.7M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
+$8.14M |
| 3 |
O
OrbiMed
New York
|
+$6.76M |
| 4 |
Millennium Management
New York
|
+$5.35M |
| 5 |
QF
QVT Financial
New York
|
+$4.61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRV
Third Rock Ventures
Boston,
Massachusetts
|
-$21M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$7.13M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$4.7M |
| 4 |
WMSA
Weiss Multi-Strategy Advisers
New York
|
-$3.46M |
| 5 |
PC
PointState Capital
New York
|
-$2.1M |
BLUE Hedge Fund Activity: Q1 2014 in Review
83 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in bluebird bio (BLUE) for Q1 2014, worth a combined $411M — up 8.7% from $378M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new BLUE positions and 9 closed out — a net gain of 4 holders — while 39 added to existing stakes and 17 trimmed.
The largest buyer was Camber Capital Management, adding an estimated $11.7M. The largest seller was Third Rock Ventures, cutting an estimated $21M.
- 83 institutional investors held bluebird bio (BLUE) as of Q1 2014, up from 81 in Q4 2013.
- Funds reported $411M of bluebird bio stock for Q1 2014, up 8.7% quarter-over-quarter.
- 13 funds opened new bluebird bio positions in Q1 2014 and 9 closed out, a net change of +4 holders.
- The largest bluebird bio buyer in Q1 2014 was Camber Capital Management, an estimated $11.7M added.
- The largest bluebird bio seller in Q1 2014 was Third Rock Ventures, an estimated $21M sold.
Based on aggregated 13F filings for Q1 2014.